SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Acquired by Prudent Man Advisors LLC

Prudent Man Advisors LLC boosted its position in SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 15.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,155 shares of the exchange traded fund’s stock after purchasing an additional 1,771 shares during the quarter. Prudent Man Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $1,300,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Affinity Asset Advisors LLC raised its holdings in shares of SPDR S&P Biotech ETF by 105.4% during the second quarter. Affinity Asset Advisors LLC now owns 37,550 shares of the exchange traded fund’s stock valued at $3,481,000 after buying an additional 737,550 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in SPDR S&P Biotech ETF by 30.3% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,136,000 shares of the exchange traded fund’s stock valued at $297,575,000 after acquiring an additional 730,000 shares in the last quarter. Mirae Asset Securities USA Inc. acquired a new position in SPDR S&P Biotech ETF during the 2nd quarter worth $55,626,000. Assetmark Inc. grew its stake in shares of SPDR S&P Biotech ETF by 72,653.0% in the third quarter. Assetmark Inc. now owns 589,299 shares of the exchange traded fund’s stock worth $58,223,000 after purchasing an additional 588,489 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of SPDR S&P Biotech ETF by 68.7% in the first quarter. Jane Street Group LLC now owns 961,082 shares of the exchange traded fund’s stock worth $91,197,000 after purchasing an additional 391,333 shares in the last quarter.

SPDR S&P Biotech ETF Stock Down 5.3 %

Shares of NYSEARCA XBI opened at $91.83 on Monday. The stock has a market cap of $7.00 billion, a P/E ratio of 11.47 and a beta of 1.11. The firm’s 50-day simple moving average is $98.95 and its 200 day simple moving average is $96.17. SPDR S&P Biotech ETF has a fifty-two week low of $69.32 and a fifty-two week high of $105.47.

About SPDR S&P Biotech ETF

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.